Name: | Description: | Size: | Format: | |
---|---|---|---|---|
2.04 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Circulating tumor cells (CTCs) have a potential role as the missing renal cell carcinoma (RCC) biomarker. However, the available evidence is limited, and detection methods lack standardization, hindering clinical use. We performed a systematic review on CTC enrichment and detection methods, and its role as a biomarker in RCC. Full-text screening identified 54 studies. Reviewed studies showed wide heterogeneity, low evidence level, and high risk of bias. Various CTC detection platforms and molecular markers have been used, but none has proven to be superior. CTC detection and CTC count seem to correlate with staging and survival outcomes, although evidence is inconsistent. CTC research is still in an exploratory phase, particularly in RCC. Further studies are still necessary to achieve a standardization of techniques, molecular markers, CTC definitions, and terminology. This is essential to ascertain the role of CTCs as a biomarker and guide future liquid biopsy research in RCC.
Description
© 2021 Elsevier B.V. All rights reserved.
Keywords
Biomarker Circulating tumor cells Liquid biopsy Metastases Renal cell carcinoma
Pedagogical Context
Citation
Crit Rev Oncol Hematol. 2021 Apr 20;161:103331
Publisher
Elsevier